Enterprise Value
111.5B
Cash
7.098B
Avg Qtr Burn
N/A
Short % of Float
1.47%
Insider Ownership
0.10%
Institutional Own.
86.85%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Tecartus® (brexucabtagene autoleucel) (CAR-T) Details Leukemia, B-cell acute lymphoblastic leukemia, Acute lymphoblastic leukemia | Approved Quarterly sales | |
Trodelvy® (sacituzumab govitecan-hziy) Details Cancer, Breast cancer, ER+/HER2- breast cancer | Approved Quarterly sales | |
Veklury® (Remdesivir) Details COVID-19 | Approved Quarterly sales | |
Lenacapavir capsid inhibitor (GS-6207) Details Human immunodeficiency virus | Approved Quarterly sales | |
Yescarta® Details Lymphopenia, B-cell lymphoma | Approved Quarterly sales | |
Bulevirtide (Hepcludex®) Details Hepatitis Delta Virus | BLA Resubmission | |
Obeldesivir (GS-5245) Details COVID-19 | Phase 3 Update | |
Lenacapavir Details Human immunodeficiency virus | Phase 2 Data readout | |
Etrumadenant Details Colorectal cancer | Phase 2 Data readout | |
Yescarta Details Lymphopenia, B-cell lymphoma | Phase 2 Interim update | |
Trodelvy® (sacituzumab govitecan-hziy) comb w/KEYTRUDA® Details Cancer, Non-small cell lung carcinoma | Phase 2 Update | |
Magrolimab+Azacitidine Details High risk myelodysplastic syndromes | Failed Discontinued |